Imatinib Drug Market Size, Share & Trends Analysis Report, by Drug Form (Tablet and Capsules), by Application (Blood Cancer (Leukemia and Other Blood Cancers), Gastrointestinal Stromal Tumors (GIST), Skin Tumors (Dermatofibrosarcoma Protuberans), and Other Tumors) and Forecast Period, 2020-2026.
The global imatinib drug market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include the prevailing incidence of leukemia across the globe and an increase in the adoption of imatinib drug by healthcare professionals. Gastrointestinal Stromal Tumor (GIST) has shown significant growth in the imatinib drug demand which is anticipated to capture a decent market share. GIST is a type of tumor that arises in the gastrointestinal tract. The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumor cells. However, the high cost of imatinib drug and the presence of several substitutes of the drug in the market such as Tarceva, Sprycel and Tasigna restricting the growth of the market.
The global imatinib drug market is segmented based on drug form, and application. Based on drug form, the market is classified into tablets and capsules. Based on application the market is classified into blood cancer (leukemia and other blood cancers), gastrointestinal stromal tumors (GIST), skin tumors (dermatofibrosarcoma protuberans), and other tumors such as systemic mastocytosis. Geographically, the global imatinib drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a major share in the market owing to the growing concern towards healthcare.
The major companies providing imatinib drugs include Dr. Reddy’s Laboratories, Ltd, Lupin, Ltd., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industry, Ltd. The introduction of generic drugs by most of these players is expected to impact the market value. For instance, in September 2017, Mylan N.V. announced the U.S. launch of Imatinib Mesylate Tablets in 100 mg and 400 mg generic version. Mylan received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for this product. Imatinib Mesylate tablets can be used for multiple indications including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hyper eosinophilic syndrome (HES) and aggressive systemic mastocytosis (ASM).
Research Methodology
The market study of the global Imatinib Drug market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in the reports.
Secondary Sources Include:
The report is intended for pharmaceutical drug manufacturers, suppliers, and distributors and government agencies for overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
The Report covers:
The global imatinib drug market is estimated to grow significantly during the forecast period. The major factors encouraging market growth include the prevailing incidence of leukemia across the globe and an increase in the adoption of imatinib drug by healthcare professionals. Gastrointestinal Stromal Tumor (GIST) has shown significant growth in the imatinib drug demand which is anticipated to capture a decent market share. GIST is a type of tumor that arises in the gastrointestinal tract. The drug targets KIT and PDGFRA (platelet-derived growth factor receptor A) proteins blocking the growth of tumor cells. However, the high cost of imatinib drug and the presence of several substitutes of the drug in the market such as Tarceva, Sprycel and Tasigna restricting the growth of the market.
The global imatinib drug market is segmented based on drug form, and application. Based on drug form, the market is classified into tablets and capsules. Based on application the market is classified into blood cancer (leukemia and other blood cancers), gastrointestinal stromal tumors (GIST), skin tumors (dermatofibrosarcoma protuberans), and other tumors such as systemic mastocytosis. Geographically, the global imatinib drug market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to hold a major share in the market owing to the growing concern towards healthcare.
The major companies providing imatinib drugs include Dr. Reddy’s Laboratories, Ltd, Lupin, Ltd., Mylan N.V., Novartis AG. and Teva Pharmaceutical Industry, Ltd. The introduction of generic drugs by most of these players is expected to impact the market value. For instance, in September 2017, Mylan N.V. announced the U.S. launch of Imatinib Mesylate Tablets in 100 mg and 400 mg generic version. Mylan received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for this product. Imatinib Mesylate tablets can be used for multiple indications including Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hyper eosinophilic syndrome (HES) and aggressive systemic mastocytosis (ASM).
Research Methodology
The market study of the global Imatinib Drug market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Authentic public databases
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for pharmaceutical drug manufacturers, suppliers, and distributors and government agencies for overall market analysis and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
- Global Imatinib Drug Market Research and Analysis by Drug Form
- Global Imatinib Drug Market Research and Analysis by Application
The Report covers:
- Comprehensive research methodologies of the global imatinib drug market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global imatinib drug market.
- Insights about market determinants which are stimulating the global imatinib drug market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Apotex Inc.
- Cipla, Inc.
- Dr. Reddy’s Laboratory, Ltd.
- Glenmark Pharmaceutical, Ltd.
- Lupin, Ltd.
- Mylan N.V.
- Novartis AG
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industry, Ltd.
